Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 595-598

  Prajoko, Yan Wisnu ^a   Aryandono, Teguh ^b  

^a DIPONEGORO UNIVERSITY   (Indonesia)

^b GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Locally advanced breast cancer; Neoadjuvant chemotherapy; NF B; Pathological response

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894678155     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.595     Document Type: Article

References (17)

1. Barre B, Coqueret O, Perkins ND (2010). Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle, 9, 4795-804.
2. Basseres DS, Baldwin AS (2006). Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene, 25, 5817-30.
3. Bourgarel-Rey V, Vallee S, Rimet O, et al (2001). Involvement of nuclear factor b in c-myc induction by tubulin polymerization inhibitors. Mol Pharmacol, 59, 1165-70.
4. Chang JC, Hilsenbeck SG (2004). Prognostic and predictive markers. In: Harris JR et al, (eds) Diseases of The Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, pp.675-96.
5. Chen ZS, Tiwari AK (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J, 278, 3226-45.
6. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O (2006). Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon, 4, 211-9.
7. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C (2008). Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol, 615, 223-50.
8. Ghavami S, Hashemi M, Ande SR, et al (2009). Apoptosis and cancer: mutations within caspase genes. J Med Genet, 46, 497-510.
9. Godwin P, Baird AM, Heavey S, Barr MP, Gately K (2013), Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol, 3, 1-10.
10. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al (2005). Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol, 23, 7098-104.
11. IARC (2008). GLOBOCAN 2008, Section of Cancer Information.
12. Jones RL, Rojo F, A'Hern R, et al (2011). Nuclear NF-kappa B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Path, 64, 130-5.
13. O'Gorman DM, Cotter TG (2011). Molecular signals in anti-apoptotic survival pathways. Leukemia, 15, 21-34.
14. Schott AF, Hayes DF (2012). Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol, 30, 1747-9.
15. Smith IC, Heys SD, Hutcheon AW, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20, 1456-66.
16. Vobořilová J, Němcová-Fürstová V, Neubauerová J, et al (2011). Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs, 29, 411-23.
17. Von Minckwitz G, Untch M, Blohmer JU, et al (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 30, 1-10.